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Background: The aims of this prospective study were to analyze the predictors of postoperative sleep disturbance
after esophagectomy for cancer and to identify patients at risk for postoperative hypnotic administration.
Methods: Sixty two consecutive patients who underwent cancer-related esophagectomy were enrolled in this study
from May 2011 to February 2012. Data about perioperative management, postoperative complications, ICU stay, and
vasopressor, hypnotic, and painkiller administration were retrieved. The EORTC QLQ-C30 was used and global quality of
life (QL2 item) and sleep disturbance (SL item) were the primary endpoints. Univariate and multivariate analyses were
performed.
Results: Postoperative request of hypnotics independently predicted bad quality of life outcome. Sleep disturbance
after esophagectomy was independently predicted by the duration of dopamine infusion in the ICU and the daily
request of benzodiazepines. Even in this case, only sleep disturbance at diagnosis revealed to be an independent
predictor of hypnotic administration need. ROC curve analysis showed that sleep disturbance at diagnosis was a good
predictor of benzodiazepine request (AUC = 73%, P = 0.02).
Conclusions: The use of vasopressors in the ICU affects sleep in the following postoperative period and the use of
hypnotics is neither completely successful nor lacking in possible consequences. Sleep disturbance at diagnosis can
successfully predict patients who can develop sleep disturbance during the postoperative period.
Keywords: Esophageal cancer, Esophagectomy, Postoperative management, Sleep disturbanceBackground
Esophageal cancer is an increasingly common cancer with
a poor prognosis. Its incidence has risen steadily over re-
cent decades, and it is now the fastest rising solid tumor in
most Western countries [1]. Nowadays, combined modal-
ity treatment protocols, such as neoadjuvant radiation and/
or chemotherapy followed by esophagectomy, are the
standard treatment since meta-analyses of randomized tri-
als have found some survival advantages [2], especially in
patients with a complete pathologic response to neoadju-
vant therapy [3]. In a very recent and authoritative ran-
domized controlled study, preoperative chemoradiotherapy* Correspondence: marcoscarpa73@yahoo.it
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unless otherwise stated.was shown to improve survival among patients with poten-
tially curable esophageal or esophagogastric-junction
cancer [4]. Nevertheless, in spite of a limited (25% to 35%)
possibility of cure and its association with a high risk of
serious complications [5], esophagectomy remains part of
the standard treatment for patients presenting with resect-
able esophageal cancer [6].
Postoperative management of patients undergoing esoph-
agectomy is particularly challenging, requiring special
expertise that can be found mainly in high volume centers
[7]. In fact, the risk of severe postoperative complications
is high even in specialized centers [6]; moreover, postoper-
ative pain can heavily affect postoperative quality of life
[8]. Sleep disruption by painful stimuli is frequently ob-
served both in clinical and experimental conditions [9].
Furthermore, in spite of recent evidence showing that anLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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nasogastric tube is usually kept in place for the first 7 to
10 postoperative days causing constant discomfort [10].
Finally, after esophagectomy patients usually spend at
least 2 days in the ICU, where noise and full light are al-
most constant throughout the day. A recent study showed
that a range of hospital sounds have a high disruptive cap-
acity on sleep, influencing both cortical brain activity and
cardiovascular function [11]. All these premises suggest
that patients undergoing esophagectomy would need hyp-
notic drugs to cope with postoperative sleep disturbances.
In a recent systematic review, we observed that, in the
early postoperative period following esophagectomy, pa-
tients experience a significantly worsened global quality
of life and are affected by more fatigue [12]. Moreover,
we observed that postoperative pain, and its relief, are
the main predictors of early postoperative quality of life
after esophagectomy [8]. Therefore, the aims of this pro-
spective study were to analyze the predictors of postop-
erative sleep disturbance after esophagectomy for cancer




Data from a prospectively collected database including
all consecutive patients presenting with esophageal can-
cer at a tertiary referral center (the Surgical Oncology
Unit of the Veneto Institute of Oncology, Padova, Italy)
between May 2011 and September 2012, were reviewed.
Clinical and socio-demographic data including age, sex,
the type and timing of procedures carried out, and pre-
and postoperative drug administration were prospectively
recorded. The Clavien-Dindo classification of surgical com-
plications was adopted for the classification of adverse
events after surgery. Tumor-node-metastasis (TNM) stagingFigure 1 Study design.was performed according to the most recent criteria of
the International Union Against Cancer. Details con-
cerning neoadjuvant therapy and surgical techniques
have been published elsewhere [13]. The EORTC QLQ-
C30, a measure assessing the quality of life of cancer
patients, was administered to patients presenting to our
outpatient clinic following neoadjuvant therapy at hos-
pital admission for surgery and at hospital discharge.
The study was performed according to the principles of
the Declaration of Helsinki and all the patients gave
their informed consent to data collection and study
participation. The study was approved by the Ethical
Committee of the Veneto Institute of Oncology (IOV-
IRRCS) (internal code 2012/46). The study design is
outlined in Figure 1.
Administration of drugs influencing sleep during the
postoperative period
During ICU stay, pain killers, inotropics, peridural
anesthetic infusion, and hypnotic drug administration were
monitored and quantified. Standard pain control protocol
included naropine 0.2% epidural infusion (5 mL/h) and
acetaminophen 1 g i.v. tris in die. Opioids (tramadol
100 mg or morphine 5 mg) were administered if pain
persisted and, thus, upon the patients’ request. Benzo-
diazepines (lorazepam 2.5 mg, diazepam 10 mg, or lor-
metazepam 0.5 mg) were offered for insomnia to every
patient and administered upon the patients’ request. The
administration of pain killers or hypnotics upon request
was registered on the clinical records by the nurse in
charge. The daily dose requested was calculated.
Quality of life questionnaire
The EORTC QLQ-C30 is a 30-item integrated system
for assessing the generic quality of life of cancer patients
[14]. The validity and robustness of the Italian version of
Table 1 Patient and cancer characteristics
Patient characteristics
Demographics Gender 13 F/49 M
Age (years) 60 (27–84)
Symptoms
at diagnosis
Weight loss (kg) 4.5 (0–22)
Dysphonia (pts) 7 (11.3%)
Pain (pts) 33 (53.2%)
Burning (pts) 11 (17.7%)
Reflux (pts) 18 (29.0%)
Comorbidities Cardiologic comorbidities 32 (51.6%)
Pulmonary comorbidities 14 (22.6%)
Hepatic comorbidities 3 (4.8%)
Psychiatric comorbidities 2 (3.2%)
Cancer characteristics
Cancer site Upper esophagus (pts) 2 (3.2%)
Medium esophagus (pts) 8 (12.9%)
Lower esophagus (pts) 52 (83.9%)
Histotype Adenocarcinoma (pts) 43 (69.4%)
Squamous cell carcinoma (pts) 19 (30.6%)
Pathological stage
pT (pts) pN (pts) pM (pts)
T0 12 N0 34 M0 59
T1 10 N1 12 M1 3
T2 9 N2 6
T3 26 N3 8
T4 5
Esophagectomy






Feeding jejunostomy (pts) 31 (50%)






Anastomotic leaks (pts) 3 (4.8%)
Cardiologic complication (pts) 7 (11.3%)
Pulmonary complications (pts) 13 (21.0%)
Urinary complication (pts) 4 (6.5%)
Recurrent nerve lesions (pts) 4 (6.5%)
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cancer patients in 1998 [15]. It is grouped into five func-
tional subscales (role, physical, cognitive, emotional, and
social functioning) and two questions assessing overall
quality of life. In addition, there are multi-item symptom
scales (sleep, fatigue, pain, and nausea and vomiting). All
of the scales and single-item measures range in score
from 0 to 100. A high score for a functional scale repre-
sents a high/healthy level of functioning, a high score for
the global health status/quality of life represents a high
quality of life, and a high score for a symptom scale/item
represents a high level of symptomatology/problems.
The questionnaire has been validated into the Italian
language.
Statistical analysis
All statistical analyses were performed using the statistic
program STATISTICA 5.1 for Windows 7 (Statsoft Inc.).
The scores on the EORTC questionnaires were calcu-
lated according to the standard Quality of Life Group
guidelines. The mean (95% CI) or frequency (%) was
used for descriptive statistics unless otherwise described.
Comparisons and correlations were carried out with
Friedman ANOVA for paired multiple comparisons,
Mann–Whitney U-test for unpaired comparison, and
Kendall correlation test, respectively. Multiple regression
models were created with significant predictors to deter-
mine the independent contributions of the different item
scores. Receiving operator characteristics (ROC) were
assessed by curve analysis. All tests were two-sided and
a P value less than 0.05 was considered significant.
Results
Administration of drugs influencing sleep during the
postoperative period
The patient, treatment, and cancer characteristics are out-
lined in Table 1. The median ICU stay was 2 (1–8) days
long and the median epidural catheter stay was 5.2 (0–13)
days long. The median infusion length was 180 (0–5,040)
minutes for dopamine, 86 (0–2,110) for noradrenaline,
and 8.5 (0–375) minutes for dobutamine. Four patients
required benzodiazepines during the ICU stay. Once
returned in the surgical ward, the mean daily request of
diazepam, lormetazepam, and lorazepam was 0.069 (95%
CI: 0.032–0.106), 0.021 (95% CI 0.002–0.040), and 0.269
(95% CI 0.186–0.351) doses, respectively. The overall
benzodiazepine daily need was 0.358 (95% CI 0.278–
0.439). Administration of drugs influencing sleep during
the postoperative period is shown in Figure 2.
Quality of life during treatment for cancer-related
esophagectomy
In our study group, the global quality of life and emo-
tional functioning remained stable during the three stepsof the study. On the contrary, pain and sleep disturbance
significantly increased after surgery compared to after neo-
adjuvant therapy and at diagnosis (P = 0.01 and P = 0.001,
respectively). Similarly, fatigue tended to increase after
esophagectomy compared to after neoadjuvant therapy
Figure 2 Administration of drugs influencing sleep during the postoperative period.
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during the three steps of the study are shown in
Figure 3a.
Quality of life and request of drugs influencing sleep
In multivariate analysis, a daily request of hypnotics
was an independent predictor of poor quality of life
outcome (β = −0.297, P = 0.022). Emotional function
after esophagectomy was independently predicted by
the daily request of tramadol, the previous use of
benzodiazepine, and the daily request of benzodiazepines
(β = −0.354, P = 0.004; β = −0.335, P = 0.006; β = −0.242,
P = 0.043, respectively). Fatigue after esophagectomy
was independently predicted by sleep disturbance after
neoadjuvant therapy and the daily request of benzodi-
azepines (β = 0.399, P = 0.008 and β = 0.288, P = 0.051,
respectively). Sleep disturbance after esophagectomy
was independently predicted by the duration of dopamine
infusion in the ICU and the daily request of benzodiaze-
pines (β = 0.236, P = 0.049 and β = 0.318, P = 0.010, re-
spectively). The correlations between drugs influencing
sleep administration and quality of life following surgery
are outlined in Table 2.
Finally, patients who needed hypnotics during their
postoperative period in the surgical ward had a signifi-
cantly worse global quality of life compared to patients
who did not need them (P = 0.007). Moreover, they re-
ported a worse emotional function, fatigue, and pain
(P = 0.03, P = 0.01, and P = 0.04, respectively). Curi-
ously, in spite of the use of hypnotics, these patientstended to have a worse sleep disturbance (postoperative
SL item) (P = 0.08). The effect of hypnotic administration
on postoperative quality of life is shown in Figure 3b.
Predictors of hypnotic administration in the
postoperative period
In multivariate analysis, only sleep disturbance at diagnosis
proved to be an independent predictor of postoperative re-
quest of any kind of hypnotic (β = 0.472, P = 0.011). ROC
curve analysis showed that sleep disturbance at diagnosis
was a relatively good predictor of postoperative request of
any kind of hypnotic (area under the curve (AUC) of 69%,
P = 0.08). Similarly, only sleep disturbance at diagnosis
proved to be an independent predictor of postoperative
benzodiazepine request (β = 0.647, P <0.001). ROC curve
analysis showed that sleep distubance at diagnosis was a
good predictor of postoperative benzodiazepines (AUC=
73%, P = 0.02). Predictors of hypnotic administration in the
postoperative period are shown in Figure 4.
Discussion
Postoperative management of patients undergoing esoph-
agectomy is particularly challenging [7]. In fact, apart from
the risk of severe postoperative complications, postopera-
tive pain, fatigue, and sleep disturbances can heavily affect
a patient’s postoperative quality of life [8]. Following
esophagectomy, sleep disruption can occur because of
painful stimuli [9], constant discomfort caused by the
nasogastric tube [10], and the constant noise and light in
the ICU. Moreover, in the long term, almost all post-
Figure 3 Quality of life changes during the three steps of the study. (a) Prospective assessment of QLQ C30 items (Friedman ANOVA). (b)
Impact of postoperative treatment on quality of life after esophagectomy.
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when supine and heartburn may make it difficult for pa-
tients to lie flat causing sleep disruption [16]. All these
premises suggest that patients undergoing esophagectomy
would require hypnotic drugs to cope with postoperative
sleep disturbances. Therefore, the aim of this prospective
study was to analyze how hypnotic and vasopressor ad-
ministration affects postoperative sleep disturbance and
quality of life following cancer-related esophagectomy.
In our series, patients spent, on average, 2 days in the
ICU, where lights are often on for several hours per
night. The role of the pineal gland is to translate light in-
puts from the retina into chemical signals for the rest of
the body via production and secretion of melatonin to
regulate the sleep/wake cycle. Melatonin production oc-
curs on a night/day cycle and is heavily dependent on
the concentration of serotonin [17,18]. Moreover, during
ICU stay, patients often underwent inotrope and vasopres-
sor infusion for cardiovascular support. The use of ino-
tropes or vasopressors in the ICU has previously been
correlated with post-discharge anxiety [19]. Intravenousdopamine does not pass the blood–brain barrier; however,
unlike much of the rest of the mammalian brain, the
pineal gland is not isolated from the body by the
blood–brain barrier system and it has profuse blood
flow, second only to the kidney. Recently, a new role
for the D4 dopamine receptor in the pineal gland was ob-
served: by means of a circadian-related heteromerization
with adrenergic receptors their activation can limit the
levels of melatonin secreted by the pineal gland [20]. The
anatomic consideration and this new interesting observa-
tion might explain why, in our series, dopamine infusion
in the ICU proved to be an independent predictor of sleep
disturbance following esophagectomy.
In our series, sleep disturbance was significantly in-
creased after surgery compared to baseline and it was in-
dependently predicted not only by the length of dopamine
infusion but also, as expected, by daily request of benzodi-
azepines. Therefore, since in our series hypnotics were lib-
erally administered upon the patients’ request after having
reported insomnia, daily request of sedative hypnotics can
be easily considered a marker of sleep disturbance. Four
Table 2 Predictors of global quality of life and of sleep disturbance
Global quality of life after surgery predictors (R2 = 0.10) Kendall’s τ P value Multiple regression β P value
Duration of fentanest infusion in ICU −0.199 0.028 −0.148 0.244
Duration of dopamine infusion in ICU −0.208 0.022
Daily request of hypnotics in surgical ward −0.238 0.008 −0.297 0.022
Fatigue after surgery R2 = 0.28 Kendall’s τ P value Multiple regression β P value
Daily request of benzodiazepine in surgical ward 0.219 0.012 0.288 0.051
Sleep disturbance at admission 0.257 0.018 0.399 0.008
Postoperative cardiologic complications 0.186 0.033
Duration of right lung exclusion 0.187 0.036
Emotional function after surgery R2 = 0.30 Kendall’s τ P value Multiple regression β P value
Daily request of tramadol in surgical ward −0.211 0.019 −0.354 0.004
Previous use of benzodiazepine −0.255 0.005 −0.335 0.006
Daily request of benzodiazepine in surgical ward −0.275 0.002 −0.242 0.043
Duration of dopamine infusion in ICU −0.205 0.024 −0.133 0.257
Pain after surgery R2 = 0.24 Kendall’s τ P value multiple regression β P value
Cardiologic comorbidities −0.304 0.001 −0.375 0.002
Maximum PEEP used in ICU −0.224 0.016 −0.210 0.081
Duration of fentanest infusion in ICU 0.179 0.050 0.220 0.066
Daily request of benzodiazepine in surgical ward 0.187 0.040 0.157 0.189
Sleep disturbance after surgery R2 = 0.23 Kendall’s τ P value multiple regression β P value
Daily request of benzodiazepine in surgical ward 0.286 0.002 0.318 0.010
Previous use of benzodiazepine 0.260 0.004 0.234 0.052
Emotional functioning after surgery −0.197 0.030
Duration of dopamine infusion in ICU 0.198 0.031 0.236 0.049
Psychiatric comorbidities 0.245 0.007
Pain after surgery 0.198 0.031 0.231 0.057
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once they returned to the surgical ward, the mean overall
daily request of benzodiazepine was 35% of a dose and
40% for the hypnotic dose. However, in spite of the avail-
ability and the liberal use of hypnotics, these patients
tended to experience worse sleep disturbances in the early
postoperative period. Thus, the first take-home message is
that, in the postoperative period, administration of hyp-
notics upon request does not completely fulfil its goal.
Further strategies to manage postoperative insomnia fol-
lowing such a major surgery are warranted.
Moreover, it was already known that the administration
of hypnotics, such as melatonin, following minimally inva-
sive abdominal surgery, did not improve subjective sleep
quality or well-being compared with placebo [21]. Even
worse, in our observational series, we noted that pa-
tients requiring hypnotics in the surgical ward reported
an impaired emotional function and global quality of
life and worse fatigue and pain compared to patients
who did not need them. Daily request of benzodiaze-
pines in the postoperative period after esophagectomywas an independent predictor of impaired emotional
function and increased fatigue. A strong association
between depression at 3 months and receiving benzodi-
azepines in the ICU has been previously observed by
Wade et al. [19]. However, the underlying mechanism
is not clear since confounding factors might be associ-
ated with this phenomenon. Fatigue following esopha-
gectomy was also predicted by sleep disturbance after
neoadjuvant therapy and emotional function was also
predicted by the daily request of tramadol; thus, sleep
disturbances alone and postoperative pain may play a
direct role on postoperative impairment of these quality
of life aspects. Nevertheless, since daytime drowsiness
and fatigue are well known short term side effects [22],
and severe anxiety and depression and even suicide dis-
turbances might be long term bad outcomes [23,24] of
benzodiazepine use, the suspicion of a possible causa-
tive relation cannot be excluded. Therefore, although
these findings should be interpreted cautiously given
that hypnotics were not randomly assigned but were
rather administered upon patient request, at clinician
Figure 4 Predictors of request of hypnotics following esophagectomy.
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somnia should be initiated as first-line treatments in
most patients [25].
These considerations make it necessary to identify pa-
tients at risk of sleep disturbance who might benefit from
a preventive medical therapy or non-pharmacologic inter-
vention [25]. In our series, postoperative daily hypnotics
need and, in particular, daily benzodiazepine need in the
surgical ward were independently predicted by the sleep
disturbance item at diagnosis, although the accuracy of
these predictions was not high but acceptable. This simple
tool (a single question investigating the presence of sleep
disturbance in the previous week) might be used to
quickly screen patients for whom esophagectomy may be
a therapeutic option. Once they are admitted for the oper-
ation they may have a better management of postoperative
insomnia.Conclusions
In conclusion, the use of vasopressors in the ICU affects
sleep in the subsequent postoperative period, and the
use of hypnotics and, in particular, of benzodiazepines is
neither completely successful nor lacking in possible
consequences in terms of impaired emotional function
and quality of life and worse postoperative fatigue and
pain. The sleep disturbance item at diagnosis can suc-
cessfully predict patients who can develop sleep distur-
bances during their postoperative period and can beused as a quick screening test to plan further interven-
tions that might help reduce poor outcomes following
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